Trial Profile
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of AST-120 (Spherical Carbon Adsorbent) for 8 Weeks in the Treatment of Mild Hepatic Encephalopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Charcoal (Primary)
- Indications Hepatic encephalopathy
- Focus Therapeutic Use
- Acronyms ASTUTE
- Sponsors Ocera Therapeutics
- 25 May 2014 New trial record